Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Chronic Myeloid Leukemia
Both
Chronic Myeloid Leukemia
Trial Information
Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily
Time Perspective: Retrospective and Prospective
Inclusion Criteria:
- Adult patients (18 years or older) in Chronic phase CML patients who have been
treated with Imatinib 400 mg and have failed.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily
Outcome Time Frame:
At 3 months post treatment change
Safety Issue:
No
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
United States: Institutional Review Board
Study ID:
CA180-240
NCT ID:
NCT01394666
Start Date:
May 2011
Completion Date:
December 2012
Related Keywords:
- Chronic Myeloid Leukemia
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
Name | Location |
|---|
